Radiotherapy Plus Cetuximab for Squamous Cell Carcinoma of the Oral Cavity: A Multicenter Retrospective Study of 79 Patients in Japan

作者：Mitsunobu Otsuru, Souichi Yanamoto, Shin‐ichi Yamada, Koh‐ichi Nakashiro, Yosuke Harazono, Tomoyuki Kohgo, Moriyoshi Nakamura, Takeshi Nomura, Atsushi Kasamatsu, Susumu Tanaka, Tadaaki Kirita, Mitomu Kioi, Masaru Ogawa, Masashi Sasaki, Yoshihide Ota, Masahiro Umeda · 发表于：International Journal of Environmental Research and Public Health · 年份：2023 · DOI：10.3390/ijerph20054545 · 被引用次数：7 · 研究领域：Head and Neck Cancer Studies、Oral health in cancer treatment、Oral Health Pathology and Treatment

There are a few reports that focus on radiotherapy (RT) and cetuximab (CET) therapy exclusively for oral cancer. This retrospective study aimed to investigate the efficacy and safety of RT and CET therapy for locally advanced (LA) or recurrent/metastatic (R/M) oral squamous cell carcinoma (OSCC). Seventy-nine patients from 13 hospitals who underwent RT and CET therapy for LA or R/M OSCC between January 2013 and May 2015 were enrolled in the study. Response, overall survival (OS), disease-specific survival (DSS), and adverse events were investigated. The completion rate was 62/79 (78.5%). The response rates in patients with LA and R/M OSCC were 69% and 37.8%, respectively. When only completed cases were examined, the response rates were 72.2% and 62.9%, respectively. The 1- and 2-year OS were 51.5% and 27.8%, respectively (median, 14 months), for patients with LA OSCC, and 41.5% and 11.9% (median, 10 months) for patients with R/M OSCC. The 1- and 2-year DSS were 61.8% and 33.4%, respectively (median, 17 months), for patients with LA OSCC, and 76.6% and 20.4% (median, 12 months) for patients with R/M OSCC. The most common adverse event was oral mucositis (60.8%), followed by dermatitis, acneiform rash, and paronychia. The completion rate was 85.7% in LA patients and 70.3% in R/M patients. The most common reason for noncompletion was an inadequate radiation dose due to worsening general conditions in R/M patients. Although the standard treatment for LA or R/M oral cancer is conc...